2020
DOI: 10.1016/j.ijpharm.2020.119659
|View full text |Cite
|
Sign up to set email alerts
|

Bacterial vaginosis: Standard treatments and alternative strategies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
46
0
6

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 59 publications
(52 citation statements)
references
References 98 publications
0
46
0
6
Order By: Relevance
“…Treatment of bacterial vaginosis is based on the oral or vaginal administration of antibiotics, such as clindamycin and metronidazole [7]. However, some problems have been pointed out that frequent relapses occur after antibiotic treatment, and beneficial bacteria are killed.…”
Section: Introductionmentioning
confidence: 99%
“…Treatment of bacterial vaginosis is based on the oral or vaginal administration of antibiotics, such as clindamycin and metronidazole [7]. However, some problems have been pointed out that frequent relapses occur after antibiotic treatment, and beneficial bacteria are killed.…”
Section: Introductionmentioning
confidence: 99%
“…But, regrettably, the cure rates associated with MTD ranged from 50–80%, with a high recurrence rate (Schwebke & Desmond, 2011 ). One of the main reasons for treatment failure is vaginal biofilm which plays a key role not only in BV pathogenesis but also in its recurrence (Tomás et al., 2020 ). Bacterial biofilms are established when an accumulation of adherent microorganisms occurs on a living surface (Malaekeh-Nikouei et al., 2020 ).…”
Section: Resultsmentioning
confidence: 99%
“…The biofilm’s structure avoids the antimicrobial penetration in the matrix as well as the direct contact with the microorganisms. Concurrently, an increase in antibiotics resistance is detected, which leads to treatment failures (Tomás et al., 2020 ). Several studies recommend the lack of effectiveness of conventional antimicrobial treatments and high recurrence rates of BV because of their failure to destroy the vaginal biofilm in addition to their adverse effects on healthy vaginal microflora (Tomás et al., 2020 ).…”
Section: Resultsmentioning
confidence: 99%
“…Хоча протягом багатьох років одним із препаратів вибору для патогенетично обумовленого лікування бактеріального вагінозу залишається кліндаміцин [14,19,21,43], проте дослідження його фармакокінетики при місцевому введення у формі супозиторіїв демонструє широкий діапазон значень фармакокінетичних показників. На нашу думку, причиною даного феномену можуть бути певні ендогенні чинники, які варіюють у різних жінок.…”
Section: вступunclassified
“…Протягом багатьох років одним із препаратів вибору для патогенетично обумовленого лікування бактеріального вагінозу залишається кліндаміцин [14,19,21,43].…”
Section: бактеріальній вагінозunclassified